Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
NCT04591002
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Osimertinib 80 MG
Sponsor
Samsung Medical Center